Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.
Stocks · News reference
TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62
TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $8 to $62.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.07) by 14.95 percent. This is a 17.27 percent increase over losses of $(1.10) per share from the
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.